Aug. 19 at 12:52 PM
$ATNM From copilot
⭐ Clean synthesis — the executive answer
**Merck’s mRNA melanoma vaccine success does not reduce the need for Actinium — it increases it.
The vaccine only works in resected melanoma and does not address IO‑refractory disease, PD‑1 failure, solid‑tumor resistance, or microenvironment remodeling.
Merck’s strike probability rises sharply in September–November 2026, making an earlier acquisition attempt more likely.
Competitive‑denial pressure on Novartis and AstraZeneca increases accordingly.**
If you want, I can now upda
